Q-omics provides the consensus-scored GTF2F1 profile across patient tissues and cancer cell-line models. GTF2F1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, GTF2F1 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, GTF2F1 protein abundance shows 24,573 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, COAD, and GBM as cancer lineages where GTF2F1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2F1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2F1 survival associations across molecular data types. GTF2F1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2F1 RNA expression–survival associations across cancer types. High GTF2F1 expression shows unfavorable associations in ACC, LUAD and UCS, but favorable associations in SCLC, KIRC and UVM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for GTF2F1 RNA expression.
This table summarizes GTF2F1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GTF2F1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2F1 shows higher tumor expression in COAD, HNSC, KIRP, KIRC, LIHC and STAD. The COAD box plot shows higher GTF2F1 RNA expression in tumor versus normal tissue (log2 FC = +0.516, t-test p < 0.001).
This table shows molecular features associated with GTF2F1 in patient tissues and cancer cell lines. In patient samples, GTF2F1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2F1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
